Meyka AI API is live for developers.Start building.
Advertisement
Astellas Pharma Inc.

Astellas Pharma Inc. (ALPMF) Stock Competitors & Peer Comparison

See (ALPMF) competitors and their performances in Stock Market.

ALPMFPNK
HealthcareDrug Manufacturers - General
$14.20
$0.20(1.39%)
U.S. Market opens in NaNh NaNm
Advertisement

Peer Comparison Table: Drug Manufacturers - General Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
ALPMF$13.25-3.44%23.7B12.99$1.02+3.84%
BMYMP$400.00-57.46%814.6B1777.78$0.23+4.56%
RHHVF$411.25-2.70%327.4B20.21$20.35+3.02%
RHHBF$411.22-2.38%327.3B20.10$20.46+3.02%
RHHBY$49.06-0.02%315.9B19.16$2.56+3.15%
AZNCF$189.90-1.35%294.4B31.49$6.03+1.41%
NVSEF$144.14-0.25%275B20.65$6.98+3.29%
SNYNF$86.61+3.14%104.1B18.79$4.61+5.59%
GLAXF$23.54-9.46%94.4B12.32$1.91+3.81%
CHGCF$47.65+3.52%78.4B28.88$1.65+3.79%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

ALPMF vs BMYMP Comparison June 2026

ALPMF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, ALPMF stands at 23.7B. In comparison, BMYMP has a market cap of 814.6B. Regarding current trading prices, ALPMF is priced at $13.25, while BMYMP trades at $400.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

ALPMF currently has a P/E ratio of 12.99, whereas BMYMP's P/E ratio is 1777.78. In terms of profitability, ALPMF's ROE is +0.17%, compared to BMYMP's ROE of +0.39%. Regarding short-term risk, ALPMF is less volatile compared to BMYMP. This indicates potentially lower risk in terms of short-term price fluctuations for ALPMF.Check BMYMP's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions